Metraipolis › archive › dc_78fb0726255c

Durvalumab plus tremelimumab for the treatment of patients with progressive, refractory advanced thyroid carcinoma: the phase II GETNE-DUTHY trial — Europe PMC PMID:41935063

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41935063
DOI
10.1038/s41467-[numero omesso]-y
License (as archived)
solo-consultazione
Archived
2026-11-03T09:10:38.218Z
SHA-256 of the archived text
960d070e79c613c5e02c8ab4cad413e120f2358f3f97f6d1d2e50bfcf4169530
Stable URL of this page
https://metraipolis.com/documento/dc_78fb0726255c

How to cite

Durvalumab plus tremelimumab for the treatment of patients with progressive, refractory advanced thyroid carcinoma: the phase II GETNE-DUTHY trial — Europe PMC PMID:41935063 — Europe PMC (en), https://europepmc.org/article/MED/41935063 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_78fb0726255c (Metraipolis archive dc_78fb0726255c, sha256 960d070e79c613c5e02c8ab4cad413e120f2358f3f97f6d1d2e50bfcf4169530)
BibTeX
@misc{dc78fb0726255c,
  title = {Durvalumab plus tremelimumab for the treatment of patients with progressive, refractory advanced thyroid carcinoma: the phase II GETNE-DUTHY trial — Europe PMC PMID:41935063},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41935063},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_78fb0726255c; sha256 960d070e79c613c5e02c8ab4cad413e120f2358f3f97f6d1d2e50bfcf4169530},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41935063. Agents can read the archived copy with the MCP tool read_document.